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T his is a summary report of the Fall Workshop on Mass Spectrometry and Good Laboratory Prac- tices, organized by the American Society for Mass 
Spectrometry (ASMS), that was held October 28-29, 
1994, at the Sheraton Society Hill Hotel, Philadelphia, 
PA. The purpose of this report is to present our assess- 
ment of the major issues discussed at the workshop. 
The program included six invited speakers who repre- 
sented U.S. federal regulatory agencies, pharmaceuti- 
cal companies, consultants who specialize in good lab- 
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Canada. 
oratory practices (GLP) compliance, and university 
scientists with an interest in GLP issues. A poster 
session was held on the evening of 28 October. In 
addition, a major portion of the program was devoted 
to questions and discussion from the floor. Participants 
engaged in an extremely lively exchange of views and 
experiences, and it simply is not possible to acknowl- 
edge all contributors to the contents of this report by 
name. A crucial contribution to the report, however, 
was made by Denise LeBlanc, who acted as recorder 
for the workshop and produced an (inevitably incom- 
plete) 33-page transcript of the proceedings. (Copies of 
this transcript are available from Dr. Robert K. Boyd.) 
It seems advisable to include here a brief comment 
with regard to nomenclature. Regulations that pre- 
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scribe GLPs were first introduced by the U.S. Food and 
Drug Administration (FDA) in 1976 as a means to 
ensure the validity and reliability of nonclinical safety 
studies (originally they referred to toxicity testing only) 
submitted for FDA decision making. In 1983 the U.S. 
Environmental Protection Agency (EPA) issued its own 
sets of GLP regulations to cover the health and safety 
testing of agricultural and industrial chemicals under 
the Federal Insecticide, Fungicide and Rodenticide Act 
and the Toxic Substances Control Act. [Previously the 
EPA had adopted a rather different approach to qual- 
ity assurance and quality control (QA/QC), as de- 
scribed in Section A.] The term “GLP” thus began to 
acquire both a more colloquial generic meaning that 
described different approaches to QA/QC in several 
different contexts and also its original more narrow 
interpretation that referred to the FDA regulations. The 
use of the term “GLP” in the title of the ASMS Work- 
shop was intended to refer to the more generic inter- 
pretation. Possibly a less confusing title for the work- 
shop would have used the term “QA/QC” instead of 
“GLP.” 
In the following report, however, “GLP” will be 
used in its more narrow connotation-that of QA/QC 
measures required by the FDA for nonclinical tests of 
candidate therapeutants. Other regulations designed to 
ensure the reliability of analytical data will be referred 
to as QA/QC measures. From the response at the 
workshop it was clear that the GLP regulations of the 
FDA are currently those of most concern to practicing 
mass spectrometrists. It is neither possible nor desir- 
able to attempt here a complete discussion of all 
aspects of theory and practice of GLP and other ap- 
proaches to QA/QC in analytical chemistry laborato- 
ries. Huber [l] provides an excellent summary of the 
general nature of GLP regulations as defined by both 
the EPA and FDA, of the events that led to their 
establishment, and of their relationship to the require- 
ments of IS0 9000 and its variants and to various 
European codes. This summary [l] does not deal ex- 
plicitly with mass spectrometry, but provides an excel- 
lent general overview of GLP and is an important 
source of information with regard to its implementa- 
tion with respect to high-performance liquid chro- 
matography, capillary electrophoresis, and UV-visible 
spectroscopy. Topics specific to mass spectrometry 
must be viewed in this more general context. 
Workshop Objectives 
The objectives of the workshop were as follows: 
1. To establish a general framework of background 
information with regard to the approaches to qual- 
ity assurance and quality control (QA/QC) in ana- 
lytical laboratories, particularly in the context of the 
practices of the two major U.S. federal regulatory 
agencies, the EPA and the FDA. This was the objec- 
tive of the contribution from Eva Zurek of Goldman 
Associates International entitled The Regulatory 
Agencies and Their Good Laboratory Practice Regu- 
la tions. 
2. To invite representatives of the EPA and FDA to 
describe the current thinking of their respective 
agencies on QA/QC issues, particularly, but not 
exclusively, those peculiar to mass spectrometry. 
Bill Budde of the EPA discussed The Many and 
Varied Programs of the U.S. Environmental Protec- 
tion Agency and Steve Musser from the FDA de- 
scribed The Viewpoint on GLP for Mass Spectrome- 
try from the U.S. Food and Drug Administration. 
3. To have scientists involved in activities that require 
GLP compliance describe practical issues that they 
face in their regular activities. John Gilbert from 
Merck Research Laboratories discussed Quantitative 
Mass Spectrometry in a Good Laboratory Practices 
Environment and Mike Alexander from the Sandoz 
Research Institute spoke about issues of data archiv- 
ing and security. 
4. To consider attributes of mass spectrometry sys- 
tems, a better understanding of which would con- 
tribute to a more intelligent approach to QA/QC 
issues than is possible by regarding the mass spec- 
trometer as a “black-box” chromatographic detec- 
tor. To this end, Jack Henion of Cornell University 
discussed Considerations for Establishing Good 
Laboratory Practices Compliance for Qualitative 
Mass Spectrometry from an Academic Perspective. 
5. Most important of all, to facilitate an exchange of 
views among the workshop participants on what is 
clearly still an evolving, not to say contentious, 
subject. The way in which the workshop partici- 
pants seized this opportunity was highly gratifying 
to the workshop organizers, and many of the points 
summarized herein were made from the floor in this 
way. 
Unfortunately we were unable to provide appropri- 
ate attributions for all of these spontaneous contribu- 
tions. We would like, however, to acknowledge those 
participants who prepared posters, which formed the 
focus for the evening discussion session. Wayne Dun- 
can of Hewlett-Packard described GLP Features for the 
Mass Spectrometry Laboratory, Denise LeBlanc of the 
National Research Council of Canada discussed Certi- 
fied Standards and Reference Materials as QA/QC 
Tools, Bori Shushan of PE-Sciex described A Manufac- 
turer’s Perspective on Providing GLP Tools, and Paul 
Winkler of Quanterra Inc. discussed GLP Considera- 
tions for Dissipation Studies Using Thermospray 
LC/MS. In addition, some workshop participants sent 
to the organizers their impressions of what were the 
key “take-home messages”; these colleagues are ac- 
knowledged as contributors. 
The preceding first four objectives describe the goals 
for the workshop as visualized by the organizers ahead 
of time. As a result of the lively discussions from the 
floor, the proceedings took on their own form, which 
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was determined by the real-life concerns of the practic- 
ing analytical chemists present. What follows is an 
attempt to summarize these discussions. 
Overview 
In the context of analytical chemistry, the purpose of 
GLP and of other QA/QC measures is to produce 
valid analytical data by using procedures that are 
sufficiently well defined that data can be reproduced 
on demand. In addition the original data must be 
archived in such a way that an unambiguous reassess- 
ment is possible in the future. The GLP concept takes 
into account the fact that analytical measurements are 
the outcome of interactions amongst the sample (whose 
integrity must be assured), the instrumentation used to 
perform the weighing and measuring operations, and 
the analysts who perform these operations and subse- 
quently process and interpret the raw data. All of these 
interactions must be under well-defined control to 
fully satisfy GLP requirements. 
In contrast, the focus of the International Standards 
Organization (ISO) series of Quality System Standards 
is the entire quality system, including nonlaboratory 
activities such as purchasing, rather than specific labo- 
ratory activities. Recognition of conformance is 
achieved through third-party registration (private in- 
spectors accredited by the ISO). IS0 Guide 25 is a 
guide for use by calibration and testing laboratories in 
the development and implementation of their quality 
systems. This generic guide is very general, with no 
specific references to analytical chemistry. In effect, 
IS0 9000 and its variants require complete documenta- 
tion of procedures, practices, and data, with no 
mandatory controls on the quality of scientific data. In 
contrast, GLP regulations are mandatory procedures 
that must be followed by pharmaceutical and agricul- 
tural industries that seek government approval for 
their products. Both QA/QC monitoring of the scien- 
tific and technical procedures and full documentation 
of procedures and archiving of data are required in 
GLP regulations, which govern whole laboratory oper- 
ation as well as study-specific experiments; compliance 
is monitored by the appropriate government regula- 
tory agency. 
The question of laboratory accreditation by profes- 
sional or trade associations, as a possible substitute for 
GLP compliance as such, was raised at the workshop. 
The representatives of both U.S. federal regulatory 
agencies made it clear that, although laboratories might 
wish to become accredited for their own purposes 
(e.g., marketing), the legal responsibility to ensure the 
integrity of analytical data obtained in connection with 
appropriate U.S. federal laws remains with the EPA 
and FDA, and in this context accreditation by other 
bodies is irrelevant. 
The following discussion is restricted to those topics 
that turned out to be the major concerns of the partici- 
pants in the ASMS Workshop. Some of these concerns 
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were specific to mass spectrometry, whereas others 
were more general. (Each of the following topics will 
be expanded in correspondingly labeled subsections.) 
A. The different approaches to QA/QC, which range 
from highly detailed inflexible prescriptions, exem- 
plified by some (not all) EPA regulations, to perfor- 
mance-based methods in which each analytical lab- 
oratory sets up its own analytical protocols and 
monitors its own performance by imposition of 
strict quality control criteria. The latter approach 
more closely resembles the FDA definition of GLP. 
B. The amount of time and effort required to achieve 
C. 
D. 
E. 
F. 
G. 
H. 
I. 
- and maintain GLP compliance. 
“Calibration” or “standardization” or “system 
suitability” tests for analytical instruments, which 
includes mass spectrometers. 
The importance of taking great pains to write stan- 
dard operating procedures (SOPS). (To avoid possi- 
ble confusion, note that, in the IS0 nomenclature, a 
“procedure” is a general statement of policy that 
describes how, when, and by whom a task must be 
performed, and associated “work instructions” 
contain the specific details of how the laboratory or 
other operation must be conducted in particular 
cases. Under GLP, these details are included in the 
SOPS themselves.) 
Qualifications of personnel and ongoing training. 
Requirements for validation of computer-based data 
systems. 
The question of what constitutes mass spectromet- 
ric “raw data,” in the sense intended in those 
regulations that require that “raw data” be 
archived. 
The recommended storage medium for electroni- 
cally recorded data and the related question as to 
who bears the responsibility to ensure that com- 
puter hardware and software that can read and 
process the archived data will be available in the 
future. 
Questions of security of data, records, and so forth. 
ln the subsequent text no attempt has been made to 
attribute particular views to individuals, except in a 
few special cases that involve representatives of the 
EPA and FDA. 
A. Prescriptive Recipes versus Performance-Based 
Methods 
Although some U.S. EPA regulatory programs specify 
minutely detailed procedures that must be followed, 
others specify the core analytical technology and the 
performance requirements but do allow the user a 
degree of flexibility to choose from some method op- 
tions. A relatively few EPA regulatory programs allow 
the wide-open, user-defined approach closely aligned 
to the performance-based GLP model. This varied situ- 
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ation resulted because each EPA regulatory program is 
implemented by a separate office that operates under a 
different U.S. federal environmental law and that cre- 
ates regulations under the authority of that specific 
law. Some analytical methods promulgated under the 
Clean Water Act and the Safe Drinking Water Act 
regulations are quite restrictive. Perhaps the most re- 
strictive methods are those specified in the analytical 
contracts issued under the Comprehensive Environ- 
mental Response, Compensation and Liability Act (or 
“Superfund”). In addition to definition of the precise 
details of the analytical procedures, these methods 
include mandatory calibration and quality control sec- 
tions. These sections specify a regimen of calibrations, 
recovery and precision tests, and performance verifi- 
cations. Some methods and/or regulations specify how 
to determine the method detection limit (MDL) [2, 31 
and define how to report protocols and archive re- 
quirements. For example, most EPA gas chromatogra- 
phy-mass spectrometry (GC/MS) methods require a 
daily demonstration that the GC/MS system is capable 
of producing a 70-eV electron ionization (EI) spectrum 
of either decafluorotriphenylphosphine (DFTPP) or 4- 
bromofluorobenzene (BFB) that meets defined perfor- 
mance requirements [4]. These performance require- 
ments include mass accuracy, resolution checks, 
correct i3C/12C ratios, sensitivity checks, and some 
relative abundances within specified ranges. For exam- 
ple, EPA method 524.2 [5] uses a BFB verification, 
method 525.1 [6] uses a DFTPP verification, and both 
methods require determination of the MDL via the 
standard procedure 12, 31. 
The trend of recent years is toward less restrictive 
EPA methods that define the core analytical technol- 
ogy and performance requirements, but allow many 
options to permit the introduction of new technology 
as it develops, for example, improved chromatography 
columns. The EPA regulations under the Federal Insec- 
ticide, Fungicide, and Rodenticide Act and the Toxic 
Substances Control Act are aligned more closely to the 
GLP approach. The regulations under the Clean Air 
Act and Resource Conservation and Recovery Act are 
somewhere in between GLP and rigid mandatory pro- 
cedures. These laws have different legal requirements 
to deal with different political issues. Although most 
research scientists feel uncomfortable with blind com- 
pliance with rigid cookbook procedures, the latter were 
instituted to deal with some facts of life in the environ- 
mental analysis business. For example, many environ- 
mental testing laboratories are not managed by analyt- 
ical chemists, but by engineers, business people, 
lawyers, or marine biologists. In this context, one infor- 
mal survey conducted some years ago found that the 
most abundant degree among GC/MS operators in 
environmental laboratories was a B.S. in biology. In 
addition, to be profitable, most large laboratories re- 
quire GC/MS operators to run several (typically two 
to six) instruments simultaneously. Faced with these 
circumstances, it is not surprising that the EPA estab- 
lished rigid cookbook protocols to establish some de- 
gree of QA/QC. In contrast, one of the requirements of 
GLP is that personnel who undertake a specific task be 
trained and-qualified for that task, and indeed updat- 
ing of skills and qualifications also is required. 
In general, the EPA deals with a limited number of 
well-publicized target analytes in a limited number of 
matrix types and is thus faced with a manageable 
number of method prescriptions. On the other hand, 
the nature of drug discovery and development is such 
that a wide range of new substances must be handled, 
under conditions of commercial confidentiality. Thus, 
it is not feasible for FDA GLP regulations to follow the 
rigid prescriptive approach. The question of the advis- 
ability of moving all the EPA regulations to an ap- 
proach that involves performance-based methods- 
more in line with GLP philosophy-has been ad- 
dressed recently [7, 81. The negative aspects of the 
rigid prescriptive approach are well known. For exam- 
ple, the inertia to change the method prescriptions as a 
result of scientific and technological advances is well 
exemplified by the long struggle to have capillary gas 
chromatography (GC) columns incorporated into the 
published methods (which include new procedures, 
techniques, helpful hints, performance requirements, 
and tests) and to abolish the packed column methods. 
However, both of the cited commentaries 17, 81 con- 
clude that, in light of the history and current state of 
the environmental analytical laboratory industry, a 
rapid wholesale changeover of the EPA regulations to 
performance-based methods would be disastrous and 
that considerable thought will be required to initiate 
such a change even for those regulations to which it is 
best suited. 
In view of these general comments that concern the 
generally prescriptive (and thus hopefully unambigu- 
ous) approach of the EPA, it is perhaps not surprising 
that the great majority of the workshop participants 
were interested in the FDA approach to GLP. Some 
degree of ambiguity for analytical chemists may arise 
because the FDA regulations under GLP were origi- 
nally designed for toxicity tests, and the U.S. Federal 
Regulations governing nonclinical laboratory studies 
reflect these origins [91. 
B. Time and Efort Required to Achieve and 
Maintain GLP Compliance 
GLP regulations strictly apply only to any safety data 
or information generated for the purpose of submitting 
a substance, product, or process to the FDA for ap- 
proval. One participant suggested that GLP compli- 
ance may come to be a more general requirement, in 
part because of the value of demonstrating such com- 
pliance in patent disputes or liability suits. Apart from 
these legal motivations, there appeared to be a consen- 
sus that GLP procedures are beneficial to laboratories 
or companies because they provide a measure of con- 
sistency in how data are generated, processed, and 
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archived. This consistency has many benefits, for ex- 
ample, facilitating discovery of the cause of any 
anomalous data that may be produced. However, there 
is clearly an activation barrier to implementation of the 
necessary procedures to achieve GLP compliance. To 
the extent that one must record and document many 
things that are not usually considered to be worth the 
trouble, GLP can imply almost a cultural change in 
how a laboratory functions. Thus, relief from burden- 
some papeMrork is the usual reason given for the 
failure of many laboratories that have no legal neces- 
sity for GLP compliance to undertake the process. 
There is no doubt that the very openness of the GLP 
process (the antithesis of the rigid prescriptive ap- 
proach exemplified by some of the EPA regulations) 
puts a direct intellectual burden on the scientists in- 
volved. The SOPS must be carefully written, as dis- 
cussed in Section C. On a more strategic level it was 
emphasised that laboratory management must play an 
active role. The Quality Assurance Unit and the Study 
Director(s) must work together to ensure that data 
produced by the laboratory meet the highest scientific 
standards and that the documentation of how it was 
produced satisfies GLP requirements. 
C. Standard Operating Procedures 
In the GLP terminology (different from ISO; see 
Overview), the SOPS contain the details of how speci- 
fied tasks are to be conducted. An SOP must strike a 
balance between what is required for GLP compliance, 
on the one hand, and needless detail that would ham- 
string the laboratory, on the other. A hypothetical 
example discussed at the workshop involved an SOP 
for a mass spectrometer that slavishly copied from the 
manufacturer’s literature a recommendation that the 
relative humidity of the laboratory be within specified 
limits. If such a requirement were included in the SOP, 
it would be necessary to have a humidity meter (with 
a calibration traceable to MST) located in the labora- 
tory. Readings would have to be recorded each day 
and the instrument would not be available for GLP- 
compliant work on days when the humidity was out- 
side these limits, even if all performance tests indicate 
that it is working perfectly. If, in the scientific judge- 
ment of those writing the SOP, some operation is not 
necessary for reliable data to be obtained, it should not 
be included in the SOP. However, the responsible 
official(s) of the laboratory must be prepared to defend 
the decision to exclude such operations, if required. 
One speaker warned his colleagues to guard against 
allowing their enthusiasm for mass spectrometry to 
lead to neglect of other crucial operations. In the con- 
text of quantitation, whether the analytical instrument 
is a mass spectrometer that costs a half-million dollars 
or a burette costing fifty dollars, quality analytical data 
will not be obtained unless properly defined SOPS are 
prescribed for the calibration and use of balances and 
volumetric devices used to prepare standard solutions 
of the analyte. In laboratories focused on sophisticated 
modem instrumentation it is all too easy to take for 
granted these fundamental operations of weighing and 
measuring. 
It was emphasized by several speakers that proba- 
bly the single most important SOP of all is that which 
describes the procedure to change the other SOPS if 
experience suggests that modification is desirable. Lack 
of care in writing this key SOP is a frequent source of 
frustration and wasted time. 
D. Standardization of Analytical lnstrumentation 
It is common sense to check instrument performance 
each day, and GLP requirements simply formalize the 
performance and documentation of these checks. The 
discussion of this point centered on the importance of 
care in writing the appropriate SOPS to avoid need- 
lessly lengthy system checks. For example, if a particu- 
lar mass spectrometer is used to record complete 
“full-scan” mass spectra, calibration of the mass-to- 
charge ratio scale is a common sense requirement that 
might be thought to apply to all mass spectrometer 
operations. However, consider an example where the 
particular purpose of that mass spectrometer is liquid 
chromatography-mass spectrometry (LC/MS) analysis 
in the selected ion monitoring (SIM) mode. The impor- 
tant performance criteria in such cases might be reten- 
tion time, chromatographic peak shape, sensitivity, 
system precision, and linear dynamic range, all of 
which can be checked simultaneously by injections of 
appropriate standard solutions (i.e., by a performance- 
based method). If one or more of the last three of these 
criteria has slipped from predetermined required val- 
ues, deterioration of the mass-to-charge ratio axis cali- 
bration might be one possible explanation that can be 
checked by using a procedure that must be spelled out 
in the appropriate SOP, for example, by comparison of 
the analyte’s complete mass spectrum with a file ver- 
sion. The point is that in this case it is, for example, the 
SIM sensitivity, precision, and linearity of response 
that are the operational performance criteria most ap- 
propriate for the SOP that describes routine instrument 
standardization. Under these particular circumstances, 
inclusion in the SOP of a mandatory complete mass 
calibration each morning could be counterproductive, 
but would be a likely element of the SOP for a system 
check if the SIM performance criteria were not met. 
This hypothetical example emphasizes yet again 
(see Section C) the importance of careful attention to 
detail in writing each SOP. Ideally, SOPS are written 
by or in consultation with the scientist(s) responsible 
for conducting the work described therein. The latter 
point also reinforces the importance of the GLP em- 
phasis that laboratories have properly qualified per- 
sonnel (see Section El. Modem mass spectrometers 
(and other analytical instruments) have become so 
easy to use that management can forget that operators 
still need ongoing training. 
216 BOYD ET AL. J Am Sot Mass Spectrom 1996, 7,211-218 
E. Qualifications and Training of Personnel 
The importance of the GLP requirement that all proce- 
dures be undertaken by appropriately qualified per- 
sonnel, with documented updated training, was em- 
phasised throughout the workshop. Those persons 
responsible for operation of mass spectrometers, for 
example, must have an understanding of the funda- 
mental physicochemical principles that underlie the 
operation of the various instruments. An example 
quoted during the workshop of the kind of problems 
that can arise if qualifications and training are not 
properly addressed involved restoration of sensitivity 
by the deliberate degradation of instrument resolution 
or increase of voltage supplied to the detector. Such 
practices are undertaken most often by operators who 
have not been trained adequately. Even chemists fa- 
miliar with the fundamentals of mass spectrometry 
can benefit from additional training, for example, in 
troubleshooting. This is particularly important, for ex- 
ample, when a liquid or gas chromatographer from 
one manufacturer is integrated with a mass spectrome- 
ter from another and with a data system from a third, 
because no single manufacturer can be held account- 
able for the overall performance of the integrated sys- 
tem. This emphasis on qualified personnel within 
performance-based GLP is very different from that in 
the prescriptive recipe approach to QA/QC exempli- 
fied by some of the earlier EPA regulations (see Sec- 
tion A), which were designed expressly for situations 
in which instrument operators are not necessarily fully 
trained. 
F. Validation of Computer-Based Data Systems 
A great deal of effort has been devoted to validation of 
the capacity of computer-based data systems to ac- 
quire, process, and store mass spectrometric data 
[lo, 111. From the floor, participants described extreme 
cases in which electronic simulation of SIM LC/MS 
peaks, which corresponded to known voltages over 
known times, were used to test the acquisition features 
of the data system. 
It is difficult to overstate the importance of the 
following FDA policy. It is absolutely essential that the 
SOPS be followed, because this is one of the most 
frequent violations of GLP regulations. Participants in 
the workshop were enthusiastic on being assured that 
validation of instrument data system software as 
stand-alone items by the user is not a GLP require- 
ment. However, documentation that the manufacturer 
has performed this procedure and a description of how 
the software was validated, must be available. As a 
cautionary note to the user, this does not mean that 
validation of the complete system is unnecessary. The 
user also must provide evidence of performance test- 
ing that demonstrates that the computer will receive 
and process data from the mass spectrometer in an 
expected and reproducible manner. An example of 
how this can be performed would be the repetitive 
injection of several certified reference materials or other 
carefully characterized compounds in which the ex- 
pected mass and response are observed in a repro- 
ducible manner. A good way to continually keep track 
of this information is through the use of control charts 
[121. Other questions discussed in the following text 
are still under active consideration by the FDA. 
G. What Constitutes “Raw Data” in the Context of 
GLP Regulations? 
This question was probably the single most debated 
point of the workshop. Unfortunately, Dr. Musser was 
not authorized to provide an ultimate definition on 
behalf of the FDA. (Archiving requirements are spelled 
out in detail in EPA regulations.1 In mass spectrome- 
try, the truly raw data consist of the detector output 
current as a function of time. Practical considerations 
dictate that the current be transformed into an electri- 
cal potential at the output of a suitable amplifier or, for 
instruments that employ pulse-counting detection 
strategies, the number of counts per acquisition period 
is used. However, because modern analytical tech- 
niques require the speed of electronic data acquisition, 
digitized signals are written to a computer disk. It is 
possible to regard the electromagnetically recorded 
digitized signals as “raw data,” but even this is not 
straightforward. For example, when full-scan mass 
spectra are acquired under rapid scan conditions such 
that the speed with which data can be written to disk 
is exceeded, the data must be preprocessed by a peak- 
find algorithm, which then determines the mass spec- 
tral peak centroid, height, and area, and writes only 
this information to disk. Further, mass spectra are 
often background-subtracted. In any event, such “raw 
data” are of use for GLP purposes only if all the 
appropriate data file information is stored along with 
the file. Such information should include, but is not 
limited to, a calibration file, details of background 
subtraction routines and/or smoothing algorithms, and 
file information such as the operator’s name, data, and 
time. 
An ambiguity of a different kind arises in the case 
of quantitative analyses by GC/MS (or LC/MS) under 
SIM conditions. Although the same questions with 
regard to the level at which the electronically pro- 
cessed data may be regarded as “raw data” apply to 
some extent, the reconstruction of the steps that lead to 
the final analytical result also requires that details of 
integration of the,GC/MS SIM peak be recorded. One 
solution is to archive a (paper) hard copy of the rele- 
vant portion(s) of the chromatogramfs), with the base- 
line(s) drawn and the current values of the user-set 
parameters of the integration algorithm listed on the 
same page together with the peak area(s) thus deter- 
mined. With regard to electronic storage of data, it was 
strongly recommended by Dr. Musser (FDA) that the 
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relevant SOP require that automated peak-find and 
integration routines be used because it is very difficult 
to obtain the same integration result twice by manual 
integration. Because it may be necessary to reproduce 
the exact integrated areas that were submitted in the 
final report from the raw data, it is more likely that the 
same result will be obtained if all the procedures 
(including software version number) are done auto- 
matically rather than manually. For cases in which 
poor chromatographic peak definition leads to “ridicu- 
lous” baselines chosen by the algorithm, the appropri- 
ate SOP should stress very strict guidelines for the 
procedures to be adopted. 
In summary, the definition of “raw data” was the 
great unanswered question from the workshop. Most 
participants stated that to protect themselves in the 
current ambiguous climate, they would continue to 
archive both the digitized “raw data” and hard copies 
of spectra or of SIM chromatograms that show base- 
lines, integrated peak areas, and the user-set parame- 
ters for the quantification algorithms. 
signed as a data-exchange method and was not in- 
tended for archival purposes. Further, the protocol 
covers only certain kinds of mass spectral data, for 
example, time-of-flight data are not covered at present. 
Another cautionary note emphasized that this kind of 
protocol inevitably involves the “lowest common de- 
nominator” in the data exchanged, so that reprocessing 
is almost always necessary. The manufacturers have a 
long-term goal to develop a full archive and exchange 
method, but do not claim to have achieved this at. 
present. 
The availability from instrument manufacturers of 
standard test data files to facilitate on-site evaluation 
of newly released software also alleviates the problems 
associated with replacement of mass spectrometer data 
systems. Nonetheless, questions remain as to whether 
or not new peak-find and integration algorithms will 
process the data in quite the same way as the original 
software. 
1. Security of Archived Data 
H. Long-Term Storage and Accessibility of 
Electronic Data 
Although this question was not seen as a major prob- 
lem in principle, it did give rise to some discussion 
after Dr. Mike Alexander’s presentation. Both physical 
The length of time for which documentation (and 
security (lock-and-key) and ‘electronic security %nited 
specimens, if applicable) must be archived varies from 
access to archived data via tightly controlled pass- 
country to country, and in extreme cases may be up to 
words) are seen to be necessary, especially when (as in 
30 years [l]. This requirement raises practical prob- 
Dr. Alexander’s laboratory) the mass spectrometers are 
lems, which were the subject of considerable discus- 
integrated into a network with a Laboratory Informa- 
sion. An illustration of a problem with electronic stor- 
tion Management System. 
. 
age of data led to a show of hands for how many 
people had successfully stored data without corruption 
on magnetic tape for 3, 4, 5, or 6 years. The number of 
raised hands dropped to zero by the time 6 years was 
called. The consensus seemed to be that data on mag- 
netic disks survived uncorrupted for about 2 years 
longer than data stored on tapes. It was thought proba- 
ble that data could be stored longer on more modern 
storage media such as optical disks and CD-ROM, but 
that it is too soon to tell for sure. Workshop partici- 
pants agreed that data storage is a real practical prob- 
lem that the regulatory agencies will have to address. 
Participants also were concerned about the avail- 
ability of data system hardware and software capable 
of accessing, processing, and displaying data acquired 
many years previously. The life cycle of data systems 
is quite short and there is no guarantee that data 
acquired by using an older data system can be read by 
a new system. Participants agreed that the regulatory 
agencies also should provide guidance on these ques- 
tions. 
The agreement among the major manufacturers of 
mass spectrometers, to adopt a protocol that permits 
transfer of data among each others’ data systems, 
should help in this regard. However, manufacturers’ 
representatives emphasized that the protocol was de- 
Conclusions 
It is clear, even from this abbreviated report, that the 
workshop raised many more questions than could be 
answered. The organizers hope that this report at least 
will serve as a focus for further progress by helping to 
define the major problems that face users and manu- 
facturers of mass spectrometers used for purposes that 
fall under the control of the EPA or FDA (or similar 
government regulatory agencies in other countries). 
The scientists from the EPA and FDA (Dr. Budde and 
Dr. Musser) who agreed to participate in the workshop 
made it clear that these matters involve not only scien- 
tific and technical questions, but also legal and politi- 
cal aspects. 
Although the workshop participants clearly ex- 
pressed understanding and respect for their scientific 
colleagues employed by the EPA and FDA and for 
their exemplary performances under fire during the 
workshop, the most prolonged applause was reserved 
for one speaker who pleaded for a return to common 
sense as a means for experienced mass spectrometrists 
to ensure consistently high quality analytical data. As 
an example of the kind of extreme anti-common sense 
proposal, which is unfortunately not unthinkable, one 
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participant mentioned a suggestion that all lens volt- 
ages would have to be recorded as measured by an 
instrument traceable to the national voltage standard 
(e.g., at NIST in the U.S. or at NRC in Canada). We 
hope that the workshop contributed to the formulation 
of regulations designed to ensure the integrity of ana- 
lytical data in a meaningful way. There are plenty of 
real problems in this regard [ 131. 
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